Evidence map›Paper›PMID 41793309›Full record

ArticleInternational journal of cancer2026

TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.

Christos Fountzilas, Spencer Rosario, Agnieszka K Witkiewicz, Henry G Withers, David L Bajor, Sarbajit Mukherjee, Joel Saltzman, Orla Maguire, Hans Minderman, Sarah Chatley and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Christos FountzilasDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.ORCID https://orcid.org/0000-0003-3837-5644
Spencer RosarioDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Agnieszka K WitkiewiczDepartment of Cellular and Molecular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Henry G WithersDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
David L BajorDepartment of Medicine, Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, Ohio, USA.
Sarbajit MukherjeeMiami Cancer Institute, Baptist Health South Florida, Miami, Florida, USA.
Joel SaltzmanDepartment of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, USA.
Orla MaguireFlow and Immune Analysis Shared Resource, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.ORCID https://orcid.org/0000-0003-0544-560X
Hans MindermanFlow and Immune Analysis Shared Resource, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Sarah ChatleyClinical Trials Office, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Mary Lynn TarquiniClinical Trials Office, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Amy WhitworthClinical Trials Office, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Jennifer JurcevicClinical Trials Office, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Hua-Hsin HsiaoDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Erik S KnudsenDepartment of Cellular and Molecular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Jason B MuhitchDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Scott I AbramsDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.ORCID https://orcid.org/0000-0002-8742-4708
Pawel KalinskiDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Brahm H SegalDepartments of Internal Medicine and Immunology, Moffitt Cancer Center, Tampa, Florida, USA.
Andrei BakinDepartment of Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.ORCID https://orcid.org/0000-0002-7728-1969
Guangwei YuanDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Chong WangDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Kristopher AttwoodAmerican College of Radiology, Reston, Virginia, USA.
Renuka IyerDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Patrick M BolandDepartment of Medicine, Rutgers Cancer Institute, New Brunswick, New Jersey, USA.

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI CANDACE S JOHNSON · 1985 to 2026
$116.6M
Associate-Director Flow and Image Cytometry Roswell Park ComprehensiveCancer CenterR50CA211108 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI HANS MINDERMAN · 2016 to 2026
$3.0M
Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USANCI NIH HHS P30 CA016056NCI NIH HHS P30CA016056NCI NIH HHS R50 CA211108NCI NIH HHS R50CA2111108
6 · The paper itself

Abstract

Immunotherapy with checkpoint inhibitors targeting the PD1/PD-L1 and CTLA4 pathways has limited activity in patients with microsatellite stable (MSS) colorectal adenocarcinoma (CRC). In a prior study, the combination of cetuximab and pembrolizumab failed to improve outcomes for patients with advanced RAS wild-type (RAS

Indexed as

AdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsCetuximabColorectal NeoplasmsMutationTumor Suppressor Protein p53AgedAntibodies, Monoclonal, HumanizedFemaleHumansMaleMiddle AgedProgression-Free SurvivalAntibodies, Monoclonal, HumanizedCetuximabpembrolizumabTP53 protein, humanTumor Suppressor Protein p53cetuximabcolorectal cancerpembrolizumabTP53

Identifiers

PMID41793309
PMCPMC13019156

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.